These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
171 related items for PubMed ID: 8278621
1. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Toyota T, Hirata Y, Ikeda Y, Matsuoka K, Sakuma A, Mizushima Y. Prostaglandins; 1993 Nov; 46(5):453-68. PubMed ID: 8278621 [Abstract] [Full Text] [Related]
3. Clinical efficacy of different doses of lipo-prostaglandin E1 in the treatment of painful diabetic peripheral neuropathy. Hong L, Zhang J, Shen J. J Diabetes Complications; 2015 Nov; 29(8):1283-6. PubMed ID: 26355026 [Abstract] [Full Text] [Related]
4. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Hoshi K, Mizushima Y, Kiyokawa S, Yanagawa A. Drugs Exp Clin Res; 1986 Nov; 12(8):681-5. PubMed ID: 3757764 [Abstract] [Full Text] [Related]
6. Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1). Scheffler P, Gross J, Markwirth T, Maier J, Schieffer H. Eur J Clin Pharmacol; 1996 Nov; 51(3-4):235-9. PubMed ID: 9010691 [Abstract] [Full Text] [Related]
7. Effects of a single drip infusion of lipo-prostaglandin E1 on vibratory threshold in patients with diabetic neuropathy. Tawata M, Nitta K, Kurihara A, Nagasaka T, Iwase E, Gan N, Inoue M, Onaya T. Prostaglandins; 1995 Jan; 49(1):27-39. PubMed ID: 7792389 [Abstract] [Full Text] [Related]
10. [Intracavernous injection of lipo prostaglandin E1 for the diagnosis of impotence: a comparative study with prostaglandin E1-CD]. Yajima M, Baba K, Minagawa N, Kohno S, Haraguchi C, Iwamoto T, Osada T. Hinyokika Kiyo; 1993 Mar; 39(3):289-92. PubMed ID: 8506803 [Abstract] [Full Text] [Related]
15. [Prostaglandin E1 in stage III and IV arterial occlusive diseases. results of a multicenter study]. Trübestein G, Ludwig M, Diehm C, Gruss JD, Horsch S. Dtsch Med Wochenschr; 1987 Jun 12; 112(24):955-9. PubMed ID: 3297596 [Abstract] [Full Text] [Related]
16. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO, Hiatt WR, Circulase investigators. J Vasc Surg; 2007 May 12; 45(5):953-60; discussion 960-1. PubMed ID: 17350216 [Abstract] [Full Text] [Related]
17. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial. Schuler JJ, Flanigan DP, Holcroft JW, Ursprung JJ, Mohrland JS, Pyke J. J Vasc Surg; 1984 Jan 12; 1(1):160-70. PubMed ID: 6384558 [Abstract] [Full Text] [Related]